Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novavax almost doubled after Sanofi struck a licensing deal worth up to $1.2bn to commercialise ...
The deal will allow Novavax to lift its "going concern" warning, which it first issued in 2023 due to having "substantial ...
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...
Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with ... to develop its own combined Covid-flu vaccine at its own cost. Shares of Sanofi rose slightly in early ...
(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement ... receive tiered royalties on any vaccine sales, said Sanofi is also taking a minority ...
French drugmaker gains access to Covid shot and other tech Sanofi also takes a small stake in Maryland-based company -rte-company state="{"_id":"0000018f-638a-d4b6 ...
Novavax shares (NVAX) surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with Sanofi (SNY, FR:SAN). Novavax shares were up 133% in recent trading at $10.11.
The Gaithersburg biotech has lifted its going-concern warning after receiving a cash infusion. Novavax Inc. is getting a big cash infusion after signing a multibillion-dollar deal with French ...
Under the licensing agreement, Sanofi will pay Novavax $500 million upfront with up to $700 million in milestone payments, making the deal worth up to $1.2 billion. The agreement also gives Sanofi ...
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...